

16 October 2025

Australian Securities Exchange
20 Bridge Street
Sydney NSW 2000

2025 Annual General Meeting Chair Address and Presentation

Melbourne, Australia – Alcidion Group Limited (ASX: ALC) (**Alcidion** or **Company**) advises in accordance with ASX Listing Rule 3.13.3, a copy of the address by Chair, Rebecca Wilson and slides to be presented at today's Annual General Meeting are attached.

ENDS

Authorised for ASX release by the Board of Alcidion Group Limited.

For further information, please contact:

Investor Relations

investor@alcidion.com

About Alcidion

Alcidion Group Limited has a simple purpose, that is, to transform healthcare with proactive, smart, intuitive technology solutions that improve the efficiency and quality of patient care in healthcare organisations, worldwide.

Alcidion offers a complementary set of software products and technical services that create a unique offering in the global healthcare market. Based on the flagship product, Miya Precision, the solutions aggregate meaningful information to centralised dashboards, support interoperability, facilitate communication and task management in clinical and operational settings and deliver Clinical Decision Support at the point of care; all in support of Alcidion's mission to improve patient outcomes.

Since listing on the ASX in 2016, Alcidion has acquired multiple healthcare IT companies and expanded its foothold in the UK, Australia, and New Zealand to now service over 400 hospitals and 87 healthcare organisations, with further geographical expansion planned. With over 20 years of healthcare experience, Alcidion brings together the very best in technology and market knowledge to deliver solutions that make healthcare better for everyone.

www.alcidion.com

© Alcidion Group Limited 2025

Chair's Address

Good afternoon shareholders, colleagues, and guests. As Chair of Alcidion I'm pleased to address you at our 2025 Annual General Meeting. This year marks an important milestone in Alcidion's 25-year journey, one characterised by transformation, growth, and unwavering commitment to modernising healthcare delivery in the UK, Australia, and New Zealand.

Alcidion's simple and ambitious purpose is to transform healthcare with proactive, smart, and intuitive enterprise technology solutions. Our focus is mission-critical, delivering solutions that directly address the most complex operational and clinical needs of hospitals and care systems across our key markets. Designed to address fragmented data and inefficient workflows to clinician workload and operational pressures, our platform is designed to enhance patient safety and provide system-wide insight.

Today, Alcidion technologies and capabilities support more than 400 hospitals, with over 130,000 active users, managing the health data, patient flow, and safety of tens of thousands of beds. Whether in the dynamic environments of UK NHS Trusts, the evolving digital landscape of Australian healthcare, or the community-centric approach in New Zealand, our solutions are enabling care that is more connected, efficient, and safe.

At the heart of our offering is Miya Precision, a modular, cloud-native platform that delivers real-time, AI-enabled clinical decision support, interoperability, and intuitive data visualisation. What sets Miya Precision apart is its flexibility. It integrates seamlessly with legacy and third-party systems, liberating existing data for smarter decision-making. It allows customers to start with 'mission-critical' modules where the need is greatest and expand over time; from patient administration and flow to mobile records, insights, and AI-powered documentation support.

Recognised for its usability, Miya Precision helps clinicians save time, improve discharge planning, and reduce both medical error and administrative burden. Recent case studies underscore reductions in bed blockages, increased time to care, and measurable efficiency gains for hospital staff and administrators.

FY25 was a record-setting year for Alcidion. Highlights include total revenue of \$40.8 million, up 10% year-on-year, with 63% derived from UK operations and 37% from ANZ. Annual Recurring Revenue now stands at \$28.5 million, up 31%, underpinning predictable, high-quality revenue growth. Underlying EBITDA of \$5.1 million represents an improvement of \$8.5 million compared with the prior year, alongside disciplined operating cost management and positive operating cash flow of \$5.8 million. Cash at year-end was \$17.7 million, with no debt, providing significant balance sheet flexibility as we pursue further growth opportunities. Our financial discipline isn't just about cost control, it's about building a robust platform with continued investment in innovation, market expansion, and shareholder value creation.

FY25 saw Alcidion secure \$73.8 million in new contract value, more than double the previous period. The landmark, 10-year \$39 million North Cumbria NHS Trust Electronic Patient Record (EPR) contract, complemented by an additional \$6.8 million contract expansion announced last month to deliver MediViewer, highlights both the trust placed in our platform and our interoperability with leading third-party solutions.

The ability to integrate scanned historical documents with our Miya Precision EPR is a tangible example of responding to evolving customer needs. Our modular strategy continues to gain traction, enabling existing customers to expand and new customers to build tailored enterprise platforms for their hospitals and communities. From North Cumbria to South Tees in the UK, and from Peninsula Health to Hywel Dda in Australia and Wales, the Miya Precision platform is establishing itself as the preferred choice to drive digital maturity and clinical efficiency.

As we move into FY26, Alcidion enters the year with \$34 million already secured in contracted revenue for the year, a strong pipeline, and an expanding installed base. The recent expansion with North Cumbria Integrated Care Trust further validates our growth strategy: continuing organic growth in established markets; evolving our product with deeper AI capabilities; targeting new territories like Canada and the Middle East and agencies such as aged care and community health; and maintaining disciplined execution focused on prudent resource allocation and agile responsiveness to market opportunities.

I was pleased to progress our Board evolution strategy with the appointment of Professor Andrew Way who adds further global healthcare experience to the Board. Andrew was most recently, the Group CEO of the Alfred Hospital and adds an important customer perspective to his Australia and UK healthcare experience. I'd like to take the opportunity to thank Victoria Weekes who retired from the Board in June 2025.

Alcidion's purpose-driven mission, disciplined financial model, and modular technology platform position the company for sustained growth, innovation, and impact. Thanks to exceptional leadership, our global Board, and the commitment of our staff, we move forward well-placed to capture market opportunities, support our customers' digital transformation goals, and deliver enhanced value to shareholders.

To our customers, thank you for your trust in our solutions. To our shareholders, thank you for your continued confidence as we execute our growth vision and build the future of Alcidion. And to the entire Alcidion team, from my fellow Board Directors and to Kate and her executive team, and every single team member who share the pride in delivering the profound benefits of our technology for sustained improvements in healthcare

Thank you.




Annual General Meeting

16 October 2025





INTRODUCTION



ACKNOWLEDGEMENT OF COUNTRY

Alcidion acknowledges the Traditional Custodians
of the land we live and work upon and pay our
respects to Elders past and present.

Alcidion Group Board



Rebecca Wilson

Non-executive Chair

Experienced company director with private, ASX-listed and not-for-profit organisations. Rebecca has held global leadership roles in marketing communication, investor relations, and corporate affairs. She has deep expertise in ESG, complex stakeholder communication, issues, crisis and risk management, transactions, and investor relations.

Rebecca is currently the Chair of Clever Culture Systems Limited (ASX:CC5), NED of Hansen Technologies (ASX:HSN) and Vitura Health Limited (ASX:VIT).



Kate Quirke

Group Managing Director/
Chief Executive Officer

25+ years of digital health sector experience. Kate has held leading management roles at large healthcare software firms, which has included large procurements and implementations of healthcare information technology across Australia, New Zealand, the United Kingdom and South-East Asia.



Daniel Sharp

Non-executive Director

25 years+ senior executive experience in investment banking and corporate finance. Daniel was previously Executive Director of Corporate Finance at Canaccord Genuity where he led dozens of IPOs, equity capital market transactions and corporate finance advisory projects across the healthcare, life sciences, technologies, financial services and general industrials sectors.

Danny is currently a NED of Botanix Pharmaceuticals (ASX:BOT), and NED of Cyban Pty Ltd.



Andrew Way

Non-executive Director

35+ years experience in senior healthcare leadership roles across both Australian and UK markets.

Andrew has been a Chief Executive for nearly 25 years, most recently as the CEO of Alfred Health in Melbourne, Victoria, finishing in 2024. Andrew has led several hospitals through major clinical and non-clinical digital transformations. Awarded an AM for his services in support of clinical research and leadership.

Andrew is currently Board Chair of HealthShare Victoria and a Director of Australian College of Health Service Management (ACHSM).



William Smart

Non-executive Director

Global digital health leader with 30+ years of experience leading transformational change in complex organisations. Based in the UK, Will is currently Digital NED, Great Western Hospitals NHS Foundation. He has held executive roles in several NHS Trusts including as Group Chief Information Officer, Royal Free London NHS Foundation Trust. Until recently,

Will served as the Global Director of External Relations, Dedalus Group where he had responsibilities across the UK and Europe and led the launch of its European built Electronic Patient Record (EPR) solution into Ireland and the UK.

Format of Meeting

01

Chair Address

02

Annual General Meeting
Presentation

03


Q&A / Voting Procedure
Overview

04

Formal Business of the
Meeting

05

General Questions



01.

Chair Address



02.

Annual General
Meeting
Presentation



FY25 Results and Growth Strategy CEO Presentation

October 2025

Snapshot



Investment Highlights



Entering FY26 with significant momentum following a record FY25 and an established growth strategy underpinned by multiple drivers




Mission-critical health informatics platform serving highly attractive global markets



High quality, diversified and long-term recurring revenue underpinning multi-year visibility



Attractive unit economics with 88% gross margin



Capital light business model with negligible capex



Long growth runway with a multi-focus approach to drive revenue via existing customer expansion, new customer wins, new markets and geographies



Structural tailwinds with digitisation of legacy health systems which are suboptimal to meet the rising demands of clinicians, administrators and patient safety



Entering FY26 with \$34m in contracted revenue, excluding anticipated contract wins



Net Cash \$17.7m, no debt

FY25 – Financial Highlights



Record year across all key financial metrics

\$40.8M

FY25 revenue

Up **10%** on pcp¹

Several new contract wins
incl. milestone \$39m+
North Cumbria contract

\$28.5M

ARR¹ (as at 30 Jun-25)

Up **31%** on 30 Jun-24

Increasing recurring
revenue base supported
by contracted
implementation and
technical services

\$73.8M

FY25 new & renewal TCV

Up **109%** on pcp

\$5.1M

Underlying EBITDA³

Up **\$8.5M** vs. (\$3.4m)
loss in FY24

EBITDA of **\$4.8M**

Fixed costs down **10%**
pcp

Significant operating
leverage

\$5.8M

Operating Cashflow
positive

Up **\$12.9M** vs. (\$7.1M)
loss in FY24

\$4.9M

Free Cash Flow

\$17.7M cash, no debt

1. Comparisons are to prior corresponding period (FY24)

2. Annual Recurring Revenue defined as the value of Support & Maintenance (S&M), hosting and/or license revenue that is contracted to be billed annually. This does not include multi-year capital licenses paid during the year or which will reoccur again upon a future contract renewal. ARR is a measure of the future annualised revenue as at a point in time.

3. Underlying EBITDA: EBITDA excluding share-based payments and one-off restructure costs

Market Drivers




Modern clinician needs and improved patient outcomes driving the digitisation of outdated, legacy systems

Transition to digital



Shift towards digital within the healthcare sector to drive clinician effectiveness and reduce medical error

Operating efficiency and workflow




Smart bed allocation, reduced length of stay and real-time patient information in burdened health systems

Increasing demand for seamless clinical solutions



Growing demand for modular and interoperable workflow solutions vs. rigid incumbent EPR solutions

Increasing industry support & funding




Increasing support and funding for digital solutions in the UK (through the NHS¹) and in Australia

Need for improved healthcare workflow to deliver efficient and productive clinicians and safer patient outcomes

Patient Journey with Miya Precision



A value proposition at every point of care





Medium Term Growth Strategy and Outlook

Growth Pillars Support a Global Platform



Multi-focus approach combining growth within existing customers, expansion in existing territories and attractive new markets and geographies

Organic Growth

1 Scale Existing Markets

- UK investment in next stage of NHS digitalisation – analog to digital
- Continued NHS investment in EPR's (ALC well positioned in several procurements)
- Expansion into more UK territories – Wales, Ireland, Scotland
- Expansion of Flow contracts in ANZ (supported by recent successes)
- Enabling move to virtual care

2 Evolve Product Functionality & Adjacencies

- Deepen AI capabilities across platform data
- Expand further into new modules of Care:
 - Virtual care & remote patient monitoring
 - Aged Care connectivity
 - Community Care – key part of reducing hospital flow & bed blockage

3 Expand into New Geographies

Priority Targets / Discussions commenced

- Canada
- Saudi Arabia / UAE

4

M&A (Buy & Build)

- Expand into new geographies
- Expand outside acute / hospital setting
- Adopt a financially disciplined, measured approach to M&A focused on expanding market share or product capabilities, ensuring acquisitions are EBITDA accretive

Scale in Existing Markets



Recent success in Australia highlights the material opportunity still existing in Australia which is complemented by larger UK opportunities

Australia



Patient Flow

- › Reduce incidence of bed blockage with effective patient flow tools
- › Alcidion gaining increased traction
- › Key opportunities:
 - **South Australia:** Several LHDs assessing Miya rollout at NAHLN
 - **Queensland:** Gov't pushing for improved solution deployment
 - **Victoria:** Leverage established presence as creation of regional systems become more prominent



Care delivery outside hospital (Virtual Care)

- › Recognition of need to support care delivery outside the hospital to:
 - a) Keep people out of hospital (at home, aged care); and
 - b) Reduce their length of stay in hospital.
- › Alcidion Virtual Care platform a leader in this category – module being implemented with existing Miya deployments

UK & NHS markets

England

- › In June 2025, Chancellor announced up to £10B in funding towards technology & digital transformation along with further staffing resourcing
- › Several EPR procurements are maturing with ALC optimistic given existing customer relationship or desired solution outlined in tender description
- › Continued interest in Flow and virtual care solutions which interoperate with larger EPR players

Wales

With Hywel Dda deploying our solution, other Welsh Health Boards are looking closely at the progress and opportunity (both Flow and EPRs).

Scotland

Scotland continues to be a market for us for modular expansion with a wider opportunity emerging in 2027 for EPR replacement.

Evolve Product Functionality




Bringing generative AI to healthcare

Advanced technologies have always been part of the Miya Precision platform.


Generative AI enables us to bring these capabilities into the clinical user interface, eliminating repetitive tasks & streamlining the capture of information.

To the right are examples of innovations that have been developed as part of the Miya AI module, taking advantage of these emerging technologies


Miya AI is the assistant, and the digital safety net, that every clinician needs.



Example Miya AI capability: Miya Scribe being used for population of clinical documentation



Example Miya AI capability: Miya Insight using generative AI to provide clinicians with a snapshot of the patient's record



Example Miya AI capability: Miya AI being used for problem detection, saving clinicians time with every clinical note.

Expand into New Geographies



Priority targets selected based on highly attractive risk / reward profile with smaller investment required to gain market entry

Canada

Win and Build



Steps taken to date:

- › Contracted experienced Canadian-based digital health specialist to assist with market entry
- › Completed market analysis
- › Opportunities already identified, qualified and progressing (incl tender documentation)
- › Reviewing M&A as potential to accelerate immediate market foothold

Next phase:

- › Hire local representation
- › Increased marketing & sales presence at trade shows

Middle East (Saudi Arabia, UAE)

Entry via Pilot Partner



Steps taken to date:

- › In country experience consultant appointed
- › Attended first trade show
- › Building credibility, referenceability & third-party validation

Next phase:

- › Invest in marketing and awareness program via high profiled industry events
- › Build partnerships/appoint distributor

Market Adjacencies



Interoperability and flexibility of platform architecture enables Miya to address critical patient challenges outside of acute setting

Aged Care

Reviewing ability to extend functionality of Miya Precision into an aged care setting


Real-time data inputs / feeds (wearables, nurse notes, clinical assessments) imputed into Miya

Ability to create dashboard alerts to deteriorating patient conditions facilitating preventative care

Community Care (Home Care, NDIS)

Similar to Aged Care, functionality of Miya Precision to be leveraged to support real-time monitoring of patient outcomes in the community

Ability to create dashboard alerts to deteriorating patient conditions facilitating preventative care



Outlook



Momentum continuing into FY26 underpinned by high contracted revenue coupled with maturing pipeline of expansion & new opportunities



As of 30 June 2025, contracted & renewal revenue to be recognised in FY26 of \$34.0M;

Contracted revenue will increase during the year as new sales are won



Targeting to be FY26 EBITDA positive and deliver positive operating cashflow

Quantum depends on timing of new contract wins



Started market testing, partner discussions, customer analysis for entry into new geographies – specifically Canada, Saudi Arabia & UAE
Progress to accelerate during FY26



Reviewing Miya platform applicability for other health verticals to complement existing capability (key targets verticals include aged care & community care)



Continuing building on referenceability in our core products to further penetrate our key markets; important role in the selection criteria



Reviewing potential M&A opportunities to accelerate growth profile

03.

Q&A / Voting Procedure Overview



04.

Formal Business of the Meeting



Financial Statements and Reports



To receive and consider the Company's Financial Statements, Directors' Report and Auditor's Report for the financial year ended 30 June 2025.

Further Information

- ▶ Matthew Gepp, Chief Financial Officer of Alcidion Group Limited and Grant Martinella of William Buck, the Company's external Auditor are present and available to answer any queries.
- ▶ Please note there is no vote required for this Item.

Resolution 1 – Adoption of Remuneration Report



To consider and, if thought fit, pass the following as an **ordinary** resolution:

“That for the purpose of section 250R(2) of the Corporations Act and for all other purposes, approval is given for the adoption of the Remuneration Report as contained in the Company’s Annual Report for the year ended 30 June 2025.”

FOR	AGAINST	PROXY’S DISCRETION	ABSTAIN
364,284,300	126,000,240	29,224,792	852,732
70.13%	24.25%	5.62%	-

Further Information

- › Voting restrictions apply to Key Management Personnel and their closely related parties.
- › The vote on this Resolution is advisory only and does not bind the Directors or Company.
- › The Board recommends that Shareholders vote in **FAVOUR** of this Resolution.
- › The Chair of the Meeting intends to vote undirected proxies in **FAVOUR** of this Resolution.

Resolution 2 – Election of Andrew Way as a Director



To consider and, if thought fit, pass the following as an **ordinary** resolution:

“That Andrew Way, who was appointed as an addition to the Board since the last Annual General Meeting of the Company and who retires pursuant to clause 20.4 of the Company’s Constitution and Listing Rule 14.4 and who, being eligible, offers himself for election, be elected as a Director of the Company.”

FOR	AGAINST	PROXY’S DISCRETION	ABSTAIN
536,107,695	1,596,196	29,219,816	487,285
94.57%	0.28%	5.15%	-

Further Information

- ▶ The Board (with Andrew Way abstaining) recommends that Shareholders vote in **FAVOUR** of this Resolution.
- ▶ The Chair of the Meeting intends to vote undirected proxies in **FAVOUR** of this Resolution.

Resolution 3 – Approval of 10% Placement Facility



Item withdrawn as announced to the ASX on 14 October 2025.



VOTING CLOSURE AND END OF FORMAL BUSINESS

05.

General Questions

The background features a large, vibrant pink circle at the top, partially overlapping a dark blue diamond shape in the center. Below the diamond are two large, bright cyan diamonds that meet at a point at the bottom. The overall composition is modern and geometric.

THANK YOU

FOR YOUR ATTENDANCE

